Table 4 Heart failure outcome trials completed in 2019: comparison of results vs. placebo

Primary composite endpoint

Primary composite outcome

16.3 vs. 21.2

 Worsening heart failure or death from CV causes

0.74 (0.65–0.85) p < 0.01

Secondary outcome

Adverse events

No. (%) active vs. placebo group (p-value)

 CV death or heart-failure hospitalization

0.75 (0.65–0.85) p < 0.001

Renal event

6.5 vs.7.2 (0.36)

Secondary outcome

Acute pancreatitis

– (–)

 Total no. of hospitalizations for heart failure and CV deaths

0.75 (0.65–0.88) p < 0.001

Diabetic ketoacidosis

0.1 vs. 0^a (–)

Secondary outcome

 Change in KCCQ total symptom score at 8 months

1.18 (1.11–1.26) p < 0.001

Secondary outcome

 Worsening renal function

0.71 (0.44–1.16)

Secondary outcome

 All-cause death

0.83 (0.71–0.97)

Exploratory outcome

 Cardiovascular death

0.82 (0.69–0.98)